Agile Therapeutics Reports Office Director Of FDA's Office Of Drug Evaluation III Affirmed Position Of Division Of Bone, Reproductive, Urologic Products, Denied Co.'s Appeal Of Dec. 21, 2017 CRL Related To NDA For Twirla